Advancing Medicines repurposing in the EU

Repurposing has emerged as an important strategy to address unmet medical need. Yet, there is still significant untapped potential for its application in the EU.

Policy recommendations on uptake of biosimilar medicines in the retail market

Positioning Statements on Physician-led Switching for Biosimilar Medicines

The Issue of Abuses of Divisional Patent Application

EU industrial policy can dramatically improve medicines manufacturing resilience and security of supply

Medicines for Europe Position on IP Action Plan – March 2021

Maintaining the exchange of critical health data – An adequacy decision on the UK data protection regime

Medicines for Europe Position Paper On Patent Linkage

Position Paper. Incentives Review The Orphan and Paediatric Incentives

Medicines for Europe Position Paper on Bolar Exemption – Feb 2021